Article Text

Download PDFPDF

Psoriasis assessment tools in clinical trials
  1. S R Feldman1,
  2. G G Krueger2
  1. 1Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
  2. 2Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT, USA
  1. Correspondence to:
    Dr S R Feldman
    Wake Forest University School of Medicine, Department of Dermatology, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA;


In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients’ quality of life are used to assess the severity of patients’ disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion’s impact on patients’ lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

  • DLQI, Dermatology Life Quality Index
  • NPF-PS, National Psoriasis Foundation Psoriasis Score
  • PASI, Psoriasis Area and Severity Index
  • PGA, physician global assessment
  • PASI
  • measurement
  • skin disease
  • quality of life

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.